Document is current
Any future updates will be listed below
-
Authors
Kagan, Amanda B.
Moses, Blake S.
Lapidus, Rena
Mott, Bryan T.
Rai, Ganesha
Anders, Nicole M.
Hoag, Stephen W.
Rudek, Michelle A. https://orcid.org/0000-0001-5739-6868
Civin, Curt I.
-
Funding
Funding for this research was provided by:
Emmert Hobbs Foundation Endowment
Maryland Technology Development Corporation (Project 1120-005)
Maryland Industrial Partnerships (Project 6502)
National Institutes of Health (T32GM066691, P30CA006973, UL1TR003098, S10RR026824)
- License Information
-
More Information
Article History
Received: 24 February 2023
Accepted: 23 April 2023
First Online: 30 May 2023
Declarations
:
: B.T.M. is an inventor on patent/patent applications related to the 2C-ARTs synthesis (US20150361088A1, expiration 01/22/2034). M.A.R. and C.I.C. are inventors on patent/patent applications related to the Treatment of Leukemia with Artemisinin Derivatives and Combinations with Other Antineoplastic Agents (US Patent Application No. 14/757, 433/US Patent 9,918,972/expiration 12/23/35). B.T.M., C.I.C., and M.A.R. are founders of Geminus Therapeutics LLC, serve on its Board of Directors and hold equity. Funding for the study described in this publication was provided by Geminus Therapeutics LLC. Under a license agreement between Geminus Therapeutics LLC and the Johns Hopkins University, Dr. Rudek and Johns Hopkins University are entitled to royalty distributions related to technology described in the study discussed in this publication. This arrangement has been reviewed and approved by the Johns Hopkins University (M.A.R.) or University of Maryland (C.I.C.) in accordance with their conflict of interest policies. All other authors declare that they have no competing interests.
